Canadian Task Force on Preventive Health Care

Selected References

Chemoprevention of Breast Cancer

Prepared  by Mark Levine, MD, MSc, FRCP(C) Chair, Steering Committee; Jean-Marie Moutquin, MD, MSc, FRSC(C), Member, Canadian Task Force; Ruth Walton, MSc, Research Associate, Canadian Task Force; John Feightner, MD, MSc, FCFP, Chair, Canadian Task Force

These recommendations were finalized by the Task Force in June 2000

 

  1. Henderson BE, Ross R, Bernstein L. Estrogen as a cause of human cancer. Cancer Res 1988;48:246-53.

  2. Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer.  Annu Rev Public Health  1996;17:47-67.

  3. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer.  J Natl Cancer Inst  1991;83:1450-9.

  4. Dawson DA, Thompson GB. Breast cancer risk factors and screening: United States, 1987.  Vital Health Stat –Series 10: Data from the National Health Survey  1990;(172):iii-iv, 1-60.

  5. Powles TJ, Hardy JR, Ashley SE, Cosgrove D, Davey JB, Dowsett M, et al. Chemoprevention of breast cancer.  Breast Cancer Res Treat  1989;14(1):23-31.

  6. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.  Lancet 1999;353:1993-2000.

  7. Early Breast Cancer Trialists' Collaborative Group.  Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet  1998;351:1451-67.

  8. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor positive tumors. N Eng J Med  1989;320:479-84.

  9. Jordan VC, Morrow M. Tamoxifen, raloxifene and the prevention of breast cancer. Endocr Rev 1999;20:253-78.

  10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.  J Natl Cancer Inst  1998;90:1371-88.

  11. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study [see comments].  Lancet  1998;352:93-7.

  12. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.  Lancet  1998;352:98-101.

  13. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.  J Natl Cancer Inst  1989;81:1879-86.

  14. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.  J Clin Oncol  1999;17:1939-55.

  15. Reis SE, Constantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial. J Natl cancer Inst 2001;93:16-21.

  16. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al.   The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.  JAMA  1999;281:2189-97.

  17. Rockhill B, Colditz G, Kaye J. Re: tamoxifen prevention of breast cancer: an instance of the fingerpost [In Process Citation].  J Natl Cancer Inst  2000;92:657-59.

  18. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.  J Natl Cancer Inst  1999;91:1829-46.

  19. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer [see comments].  N Engl J Med   2000;342:564-71.

  20. Chlebowski RT. Reducing the risk of breast cancer.  N Engl J Med  2000;343:191-8.

  21. COG Committee on Gynecologic Practice. Committee Opinion: Tamoxifen and the prevention of breast cancer in high risk women.  ACOG Today  1999;October:Number 224

Link to Full Text of this review

Link to Patient Version of the guidelines

Link to Structured Abstract of this review

Link to Summary Table of Recommendations of this review

Top of Page

CTFPHC Home Page

Reprinted in modified format by the Canadian Task Force on Preventive Health Care
Original Copyright © 2000 Canadian Medical Association.
For any technical issues please contact: webmaster@ctfphc.org
Last modified: June 11, 2001